|Articles|March 18, 2016
CRF Health’s Platform Selected in Phase III Diabetes Trial
CRF Health, a provider of eCOA solutions for the life sciences industry, announced its TrialMax® eCOA platform has been selected by a sponsor to capture more than 4.6 million data points via an integrated medical device in a Phase III diabetes program. The program encompasses 3,000 patients across 450 sites in 28 countries using diabetes care devices and patient diaries. Read the full release.
Advertisement
CRF Health, a provider of eCOA solutions for the life sciences industry, announced its TrialMax® eCOA platform has been selected by a sponsor to capture more than 4.6 million data points via an integrated medical device in a Phase III diabetes program. The program encompasses 3,000 patients across 450 sites in 28 countries using diabetes care devices and patient diaries.
Read the full release .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How Sponsors Can Modernize Tools to Support PhysiciansSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
